I calculate fair value by projecting 5-yr Unlevered FCF and discounting it via WACC, adding a terminal value for long-term growth. I adjust for net cash and shares to find the intrinsic floor.
No link added
The Oncology Anchor: Why Merck’s 46% Discount Defies the Keytruda Cliff
Merck’s 2026 narrative is a high-stakes drama centered on Keytruda , the world’s top-selling cancer drug. For years, the market has treated Merck like a "one-trick pony" due to the looming 2028 "patent cliff," where Keytruda will lose its legal protection and face generic competition.Read more
The Architect of Sovereignty: Palantir’s Premium Paradox at $149
Palantir’s journey into 2026 is the story of a "Black Box" defense contractor that successfully transformed into the central nervous system of the global enterprise. Once whispered about in the halls of intelligence agencies, the company’s Artificial Intelligence Platform (AIP) has moved from secretive government basements to the front lines of heavy industry and sovereign AI alliances.Read more